Karin S. Blanchard - Concepedia

Concepedia

Author

Karin S. Blanchard

Nivalis Therapeutics (United States)

Also Known As

K S Blanchard, KARIN S. BLANCHARD, Karin Blanchard, Karin S. Blanchard

8

Publications

1.8K

Citations

8

H-Index

29

Concepts

All Affiliations

Nivalis Therapeutics (United States)Cleveland Clinic

KS

About

Karin S. Blanchard is an author at Nivalis Therapeutics (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.4K
2	Pharmacology	4	4	285
3	Biomolecular Engineering	1	1	1.2K
4	Cell Biology	1	1	160
5	Immunology	1	1	1.2K

Karin S. Blanchard

×

7

Publications

1.8K

Citations

7

H-Index

	Year	Citations
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Jennifer A. Lockridge, Lucinda Shaw, Karin S. Blanchard, Nature Biotechnology Medicinal ChemistryViral HepatitisImmunologyAntiviral Drug DevelopmentHepatitis	2005	1.2K
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication† Karin S. Blanchard, Lucinda Shaw, Kristi Jensen, Hepatology	2005	290
Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. P A Pavco, Karyn Bouhana, Adalberto M. Gallegos, PubMed Messenger RnaTumor BiologyAngiogenesisVegf Receptor MrnaAnti-cancer Agent	2000	160
Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. Jennifer A. Sandberg, Vann P. Parker, Karin S. Blanchard, PubMed Ribozyme AdministrationPharmacological StudyClinical TherapeuticMedicineHealthy Volunteers	2000	51
Pharmacokinetics and Tissue Distribution of a Ribozyme Directed Against Hepatitis C Virus RNA Following Subcutaneous or Intravenous Administration in Mice Patrice A. Lee, Lawrence M. Blatt, Karin S. Blanchard, Hepatology	2000	49
Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers Jennifer A. Sandberg, Vann P. Parker, Karin S. Blanchard, The Journal of Clinical Pharmacology Molecular PharmacologyTherapeutic Drug MonitoringPharmacokinetic ModelingCardiovascular DiseaseClinical Therapeutic	2000	44
Acute Toxicology and Pharmacokinetic Assessment of a Ribozyme (ANGIOZYME™) Targeting Vascular Endothelial Growth Factor Receptor mRNA in the Cynomolgus Monkey Jennifer A. Sandberg, Christopher D. Sproul, Karin S. Blanchard, Antisense and Nucleic Acid Drug Development ThrombosisAngiogenesisAcute ToxicologyCardiovascular DiseaseVascular Pharmacology	2000	30

Page 1